Cerebrolysin for vascular dementia.
Review of earlier studies · 2019
- What was studied
- Six vascular-dementia trials; 597 participants
- Main finding
- Cochrane found possible cognitive and global-function signals but a weak, very low-certainty evidence base.
Cognition · SMD 0.36; 95% CI 0.13–0.58 · Three studies, 420 people; very low certainty
Reported findings and study design
Vascular-dementia review: six trials, 597 participants; no new eligible studies in the update. Follow-up 15 days–three years.
Population or model Six vascular-dementia trials; 597 participants
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cognition | SMD 0.36; 95% CI 0.13–0.58 | Three studies, 420 people; very low certainty |
| Global-function response | RR 2.69; 95% CI 1.82–3.98 | Two studies, 379; very low certainty |
| Adverse events | RR 0.91; 95% CI 0.29–2.85 | Two studies, 379; very low certainty |
| Mortality | One trial reported no deaths | Other trials did not supply usable mortality data |
Heterogeneous, high-risk-of-bias studies. Scale response is distinct from preventing dementia or mortality.
Source for these results ↗ · Reviewed 2026-10-29
Study limitations and source details
Study limitations
- High risk of bias, heterogeneity and potentially clinically small effects. No quality-of-life or caregiver-burden data; industry support where funding was reported.
Source details
Journal publication
Citation and indexed abstract checked. Full methods, funding and risk of bias have not been comprehensively appraised.
Sources checked
Citation
Cui S, Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. Cerebrolysin for vascular dementia. The Cochrane database of systematic reviews
Study source ↗ · DOI 10.1002/14651858.cd008900.pub3 · Bibliography entry · Link to this summary